Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
Villani V, Fabi A, Tanzilli A, Pasqualetti F, Lombardi G, Vidiri A, Gonnelli A, Molinari A, Cantarella M, Bellu L, Terrenato I, Carosi M, Maschio M, Telera SM, Carapella CM, Cognetti F, Paiar F, Zagonel V, Pace A. Villani V, et al. Among authors: carapella cm. Future Oncol. 2019 May;15(15):1717-1727. doi: 10.2217/fon-2018-0826. Epub 2019 Apr 12. Future Oncol. 2019. PMID: 30977687
Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.
Fabi A, Metro G, Vidiri A, Lanzetta G, Carosi M, Telera S, Maschio M, Russillo M, Sperduti I, Carapella CM, Cognetti F, Pace A. Fabi A, et al. Among authors: carapella cm. J Neurooncol. 2010 Nov;100(2):209-15. doi: 10.1007/s11060-010-0163-3. Epub 2010 Mar 30. J Neurooncol. 2010. PMID: 20352471 Clinical Trial.
Comorbidities in elderly patients with glioblastoma: a field-practice study.
Villani V, Tanzilli A, Telera SM, Terrenato I, Vidiri A, Fabi A, Zucchella C, Carapella CM, Marucci L, Casini B, Carosi M, Oppido PM, Pace A. Villani V, et al. Among authors: carapella cm. Future Oncol. 2019 Mar;15(8):841-850. doi: 10.2217/fon-2018-0524. Epub 2019 Jan 18. Future Oncol. 2019. PMID: 30656982
Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial.
Fabi A, Terrenato I, Vidiri A, Villani V, Tanzilli A, Airoldi M, Pedani F, Magri V, Palleschi M, Donadio M, Catania G, Nisticò C, Carapella C, Rudà R, Pace A, Maschio M, Telera S, Cognetti F; AINO (Associazione Italiana Neuro-Oncologia). Fabi A, et al. Future Oncol. 2021 Sep;17(26):3445-3456. doi: 10.2217/fon-2021-0300. Epub 2021 May 28. Future Oncol. 2021. PMID: 34044585
Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.
Vaccaro V, Fabi A, Vidiri A, Giannarelli D, Metro G, Telera S, Vari S, Piludu F, Carosi MA, Villani V, Cognetti F, Pompili A, Marucci L, Carapella CM, Pace A. Vaccaro V, et al. Among authors: carapella cm. Biomed Res Int. 2014;2014:351252. doi: 10.1155/2014/351252. Epub 2014 May 4. Biomed Res Int. 2014. PMID: 24877084 Free PMC article. Clinical Trial.
Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.
Metro G, Fabi A, Mirri MA, Vidiri A, Pace A, Carosi M, Russillo M, Maschio M, Giannarelli D, Pellegrini D, Pompili A, Cognetti F, Carapella CM. Metro G, et al. Among authors: carapella cm. Cancer Chemother Pharmacol. 2010 Jan;65(2):391-7. doi: 10.1007/s00280-009-1155-x. Epub 2009 Oct 22. Cancer Chemother Pharmacol. 2010. PMID: 19847425 Clinical Trial.
Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center.
Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, Moscetti L, Russillo M, Lanzetta G, Mansueto G, Pace A, Maschio M, Vidiri A, Sperduti I, Cognetti F, Carapella CM. Fabi A, et al. Among authors: carapella cm. J Exp Clin Cancer Res. 2011 Jan 18;30(1):10. doi: 10.1186/1756-9966-30-10. J Exp Clin Cancer Res. 2011. PMID: 21244695 Free PMC article.
87 results